法规知识库 · EMA 集中审评
SonoVue
sulphur hexafluoride · EMEA/H/C/000303 · 已授权
获批上市许可
2001-03-26
欧委会决定日
2026-03-18
持有人 / 申请人
Bracco International B.V.
终止日期字段
无
从产品到官方文件
文件记录
12
官方索引 12
EPAR / 审评
10
assessment / overview 等
产品信息
2
PI / presentations
其他
0
RMP / PIP 等
ATC:V08DA05
治疗领域:Ultrasonography;Echocardiography
药理分类:Contrast media
修订号:22 · 最新影响 PI 的程序:EMA/VR/0000337224
适应症(原文):This medicinal product is for diagnostic use only. SonoVue is for use with ultrasound imaging to enhance the echogenicity of the blood, or of fluids in the urinary tract which results in an improved signal to noise ratio. SonoVue should only be used in patients where study without contrast enhancement is inconclusive. Echocardiography SonoVue is a transpulmonary echocardiographic contrast agent for use in adult patients with suspected or established cardiovascular disease to provide opacification of cardiac chambers and enhance left ventricular endocardial border delineation. Doppler of macrovasculature SonoVue increases the accuracy in detection or exclusion of abnormalities in cerebral arteries and extracranial carotid or peripheral arteries in adult patients by improving the Doppler signal to noise ratio. SonoVue increases the quality of the Doppler flow image and the duration of clinically useful signal enhancement in portal vein assessment in adult patients. Doppler of microvasculature SonoVue improves display of the vascularity of liver and breast lesions during Doppler sonography in adult patients leading to more specific lesion characterisation. Ultrasonography of excretory urinary tract SonoVue is indicated for use in ultrasonography of the excretory tract in paediatric patients from newborn to 18 years to detect vesicoureteral reflux. For the limitation in the interpretation of a negative urosonography.
关键日期时间轴
来自 EMA medicines JSON 日期字段;缺失字段不展示,不补推结论。
2026-03-18 · 欧委会决定
2001-03-26 · 获批上市许可
说明书、EPAR 与其他文件
仅展示 EMA 官方 document_url;本站不下载或镜像 PDF。
EPAR / 审评资料
- 打开官方文件 ↗
SonoVue : EPAR - Procedural steps taken and scientific information after authorisation
procedural-steps-after · 2026-03-20
- 打开官方文件 ↗
SonoVue : EPAR - Risk management plan
rmp · 2025-11-24
- 打开官方文件 ↗
SonoVue : EPAR - Procedural steps taken and scientific information after authorisation (archive)
procedural-steps-after · 2025-11-24
- 打开官方文件 ↗
SonoVue-H-C-PSUSA-00002822-202009 : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation
scientific-conclusion · 2021-09-14 · EMA/359079/2021
- 打开官方文件 ↗
SonoVue-H-C-303-X-0034-G : EPAR - Assessment Report - Variation
variation-report · 2017-08-24 · EMA/CHMP/431946/2017
- 打开官方文件 ↗
SonoVue : EPAR - Summary for the public
overview · 2017-08-24
- 打开官方文件 ↗
SonoVue-H-C-303-II-0025 : EPAR - Assessment Report - Variation
variation-report · 2014-07-29 · EMA/454283/2014
- 打开官方文件 ↗
SonoVue : EPAR - Steps taken after authorisation when a cutoff date has been used
steps-after-cutoff · 2005-10-21
- 打开官方文件 ↗
SonoVue : EPAR - Procedural steps taken before authorisation
procedural-steps-before · 2005-10-21
- 打开官方文件 ↗
SonoVue : EPAR - Scientific Discussion
scientific-discussion · 2005-10-21
数据来自 EMA 官方 JSON;最终以 EMA / 欧委会文件为准。本页不自动给出安全或非安全结论。